Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373786 · ClinicalTrials.gov registry record · Phase 1
A Study of RG-012 in Subjects With Alport Syndrome
A Phase 1 study of Alport Syndrome, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 7
- Study locations
NCT03373786 is a Phase 1 study of Alport Syndrome that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 4 participants, below the 618-participant average among 5 other Alport Syndrome trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT03373786, a Phase 1 study of Alport Syndrome, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 1, open-label, multi-center study of the safety, pharmacodynamics, and pharmacokinetics of RG-012 administered to subjects with Alport syndrome.
Conditions Studied
Interventions
- DRUG RG012
Study Locations (7)
California
- eStudySite - La Mesa
- Academic Medical Research Institute - Los Angeles
- Apex Research of Riverside - Riverside
Florida
- Eminence Medical & Clinical Research - Tampa
Texas
- Houston Nephrology Research - Cypress
Utah
- Utah Kidney Research Institute - Salt Lake City
Wisconsin
- Allegiance Research Specialists, LLC - Wauwatosa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-12-22 |
| Est. Completion | 2019-05-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03373786
The ClinicalTrials.gov registry entry for NCT03373786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 618-participant average among 5 other Alport Syndrome trials with a reported enrollment target (99% lower). The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alport Syndrome appearing as the primary indexed condition, and to 1 intervention - of which RG012 is the first listed.
NCT03373786 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT03373786 about?
NCT03373786 is a clinical study titled "A Study of RG-012 in Subjects With Alport Syndrome". This is a Phase 1, open-label, multi-center study of the safety, pharmacodynamics, and pharmacokinetics of RG-012 administered to subjects with Alport syndrome.
What is the current status of trial NCT03373786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2017-12-22. Estimated completion is 2019-05-20.
What conditions does trial NCT03373786 study?
This clinical trial studies the following conditions: Alport Syndrome.
What interventions are being tested in trial NCT03373786?
The interventions under investigation include: RG012 (DRUG).
Who is sponsoring clinical trial NCT03373786?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03373786 being conducted?
This trial has 7 study locations across California, Florida, Texas, Utah, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alport Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
NEPTUNE Match Study
RECRUITING · NA
-
ASF Alport Patient Registry
RECRUITING
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.